文献速递白血病

伊马替尼治疗慢性髓性白血病随机研究:标准剂量递增与积极剂量递增的比较

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation.
PubMed 文献 · Blood Adv · 2019-01-01

2007年开展的前瞻性随机研究比较积极剂量递增(B组,n=123)与欧洲白血病网标准剂量递增(A组,n=122)治疗慢性髓性白血病。B组未达完全细胞遗传学缓解或主要分子学反应时伊马替尼增至600 mg。早期积极剂量递增未能在12个月产生更好的分子学反应,但耐受良好而早期反应不足者可能获益。

要点

  • 6个月完全细胞遗传学缓解率A组69.4% vs B组78.7%。
  • 12个月和24个月主要分子学反应率两组相似。
  • 24个月因失败退出累积发生率A组9.2% vs B组2.5%。

核心结论

  • 早期积极剂量递增未能在12个月产生更好的分子学反应。
  • 对于耐受伊马替尼良好但早期时间点反应不足的患者,积极剂量递增可能有助于获得更好的结局。

研究设计与样本

  • 2007年开展的前瞻性随机研究,比较积极剂量递增(B组,n=123)与欧洲白血病网提出的标准剂量递增(A组,n=122)。
  • B组患者若3个月未达完全细胞遗传学缓解或6个月未达主要分子学反应(MR3),伊马替尼增至600 mg。
  • 研究注册号为#R000000965。

主要发现

  • 6个月完全细胞遗传学缓解率A组69.4% vs B组78.7%。
  • 12个月和24个月MR3率A组分别为52.1%和70.0%,B组分别为58.7%和68.3%,两组相似。
  • 24个月因失败(无加速期/急变期)退出累积发生率A组9.2% vs B组2.5%。
  • 3个月和6个月时,B组有90例(74.4%)按方案将伊马替尼剂量增至600 mg。
  • 按方案接受增量治疗的42例中25例(60.0%)在12个月达到MR3,而未接受增量治疗的40例中仅14例(35.0%)达到MR3(P < .05)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2007, we conducted a prospective randomized study to compare an aggressive dose escalation (group B, n = 123) with the standard dose escalation proposed by European LeukemiaNet (group A, n = 122). In group B, if patients did not achieve a complete cytogenetic response (CCyR) at 3 months or did not achieve a major molecular response (MR3) at 6 months, imatinib was increased to 600 mg. At 6 months CCyR was achieved in 69.4% and 78.7% of patients in groups A and B, respectively. The rate of MR3 at 12 months and 24 months were similar in group A (52.1% and 70.0%) and group B (58.7% and 68.3%). The cumulative incidence of withdrawal by failure without accelerated/blast phase was higher in group A than in group B (9.2% vs 2.5% at 24 months). At 3 and 6 months, the protocol called for the imatinib dose to increase to 600 mg in 90 patients (74.4%) in group B. Among the 42 patients who received increased dose according to the protocol, 25 (60.0%) achieved MR3 at 12 months, whereas only 14 (35.0%) of 40 patients who did not receive an increased dose achieved MR3 (P < .05). The number of patients who withdrew from this study was similar (group A, 20%; group B, 21%). The early aggressive dose escalation failed to produce a better molecular response at 12 months. However, for patients who tolerate imatinib well, but show inadequate response at an early time point, aggressive dose escalation may contribute to achieving a better outcome. This study was registered at http://www.umin.ac.jp/ctr/ as #R000000965.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Miyamura K, Ohnishi K, Ohtake S, et al. Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation. Blood Adv. 2019. PMID: 30705033. doi:10.1182/bloodadvances.2018025981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。